NDA 210455 · Janssen Prods
Symtuza
Cobicistat, Darunavir, Emtricitabine, Tenofovir Alafenamide Fumarate · Oral · Protease Inhibitor; Cytochrome P450 3A Inhibitor; Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor
Last checked: Nov 19, 2026Latest source record: Mar 31, 2023 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2018
Jul 17, 2018
Approved uses
2
Original approval plus efficacy supplements
Registered trials
155
48 Phase 3, 6 recruiting
FAERS reports
2,754
2,063 serious, 110 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: POST TREATMENT ACUTE EXACERBATION OF HEPATITIS B Severe acute exacerbations of hepatitis B (HBV) have been reported in patients who are coinfected with HIV-1 and HBV and have discontinued products containing emtricitabine and/or tenofovir disoproxil fumarate (TDF), and may occur with discontinuation of SYMTUZA. Closely monitor hepatic function with both clinical and laboratory follow-up for at least several months in patients who are coinfected with HIV-1 and HBV and discontinue SYMTUZA. If appropriate, anti-hepatitis B therapy may be warranted [see Warnings and Precautions (5.1) ] . WARNING: POST TREATMENT ACUTE EXACERBATION OF HEPATITIS B See full prescribing information for complete boxed warning. Severe acute exacerbations of hepatitis B (HBV) have been reported in patients who are coinfected with HIV-1 and HBV and have discontinued products containing emtricitabine and/or...
What it is approved for
From the label in effect Apr 17, 2026.
1. INDICATIONS AND USAGE SYMTUZA is indicated as a complete regimen for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults and pediatric patients weighing at least 40 kg: who have no prior antiretroviral treatment history or who are virologically suppressed (HIV-1 RNA less than 50 copies per mL) on a stable antiretroviral regimen for at least 6 months and have no known substitutions associated with resistance to darunavir or tenofovir. SYMTUZA is a four-drug combination of darunavir (DRV), a human immunodeficiency virus (HIV-1) protease inhibitor, cobicistat (COBI), a CYP3A inhibitor, and emtricitabine (FTC) and tenofovir alafenamide (TAF), both HIV-1 nucleoside analog reverse transcriptase inhibitors, and is indicated as a complete regimen for the treatment of HIV-1 infection in adults and pediatric patients weighing at least 40 kg: who have no prior antiretroviral treatment history or who are virologically suppressed (HIV-1 RNA less than 50 copies per mL) on a stable antiretroviral regimen for at least 6 months and have no known substitutions associated with resistance to darunavir or tenofovir. ( 1 )
Mechanism: SYMTUZA is a fixed-dose combination of antiretroviral drugs darunavir (plus the CYP3A inhibitor cobicistat), emtricitabine, and tenofovir alafenamide [see Microbiology (12.4) ] .
Therapeutic areas: Infectious disease and vaccines · Rare and genetic disease
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Mar 2, 2020 Supplement 9 · Efficacy LabelLetterPediatric Medical Review
- Jul 17, 2018 Original approval · Type 4 - New Combination LabelLetterReview
1 products under this application
- SYMTUZA · COBICISTAT 150MG; DARUNAVIR 800MG; EMTRICITABINE 200MG; TENOFOVIR ALAFENAMIDE FUMARATE EQ 10MG BASE · TABLET, ORAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Cobicistat" as an intervention, any sponsor and status, largest first.
- RPV+DRV/Cobi Dual Therapy in Subjects With HIV Controlled InfectionPivotal-lookingStatus unknown
A.O. Ospedale Papa Giovanni XXIIIAcademic, hospital or other
NCT04064632 · 1,609 participants · Start Feb 1, 2017 · Primary completion Jun 13, 2019
Drug: Rilpivirine + darunavir/cobicistat · For: HIV Infection
Sites: Bergamo, Italy
- Study to Evaluate Switching From a TDF-Containing Combination Regimen to a TAF-Containing Fixed Dose Combination (FDC) in Virologically-Suppressed, HIV-1 Positive ParticipantsPivotal-lookingCompleted
Gilead SciencesGilead Sciences (GILD)
NCT01815736 · 1,443 participants · Start Mar 27, 2013 · Primary completion Mar 16, 2015
Drug: E/C/F/TAF; E/C/F/TDF and 5 more · For: HIV; HIV Infections
Sites: Birmingham, Alabama; Phoenix, Arizona; Little Rock, Arkansas · 167 sites in all
Janssen R&D IrelandJohnson & Johnson (Janssen) (JNJ)
NCT02269917 · 1,149 participants · Start Mar 2015 · Primary completion Feb 2017
Drug: D/C/F/TAF; Boosted Protease Inhibitor (bPI) and 1 more · For: Human Immunodeficiency Virus Type 1
Sites: Phoenix, Arizona; Bakersfield, California; Beverly Hills, California · 79 sites in all
- Study to Evaluate the Safety and Efficacy of E/C/F/TAF Versus E/C/F/TDF in HIV-1 Positive, Antiretroviral Treatment-Naive AdultsPivotal-lookingCompleted
Gilead SciencesGilead Sciences (GILD)
NCT01797445 · 872 participants · Start Mar 12, 2013 · Primary completion Sep 19, 2014
Drug: E/C/F/TAF; E/C/F/TDF and 2 more · For: HIV; HIV Infections
Sites: Birmingham, Alabama; Phoenix, Arizona; Los Angeles, California · 117 sites in all
- Study to Evaluate the Safety and Efficacy of E/C/F/TAF (Genvoya®) Versus E/C/F/TDF (Stribild®) in HIV-1 Positive, Antiretroviral Treatment-Naive AdultsPivotal-lookingCompleted
Gilead SciencesGilead Sciences (GILD)
NCT01780506 · 872 participants · Start Dec 26, 2012 · Primary completion Aug 26, 2014
Drug: E/C/F/TAF; E/C/F/TDF and 2 more · For: HIV; HIV Infections
Sites: Birmingham, Alabama; Phoenix, Arizona; Los Angeles, California · 117 sites in all
Janssen Sciences Ireland UCJohnson & Johnson (Janssen) (JNJ)
NCT02431247 · 725 participants · Start Jul 6, 2015 · Primary completion Mar 2, 2017
Drug: Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide FDC; DRV/COBI FDC and 4 more · For: Immunodeficiency Virus Type 1, Human
Sites: Birmingham, Alabama; Phoenix, Arizona; Bakersfield, California · 80 sites in all
- Study to Evaluate the Safety and Efficacy of Stribild Versus Ritonavir-Boosted Atazanavir Plus Truvada in Human Immunodeficiency Virus, Type 1 (HIV-1) Infected, Antiretroviral Treatment-Naive AdultsPivotal-lookingCompleted
Gilead SciencesGilead Sciences (GILD)
NCT01106586 · 708 participants · Start Apr 2010 · Primary completion Sep 2011
Drug: Stribild; ATV and 6 more · For: HIV; HIV Infections
Sites: Phoenix, Arizona; Little Rock, Arkansas; Beverly Hills, California · 146 sites in all
- Study to Evaluate the Safety and Efficacy of Stribild Versus Atripla in Human Immunodeficiency Virus, Type 1 (HIV-1) Infected, Antiretroviral Treatment-Naive AdultsPivotal-lookingCompleted
Gilead SciencesGilead Sciences (GILD)
NCT01095796 · 707 participants · Start Mar 2010 · Primary completion Aug 2011
Drug: Stribild; Atripla and 2 more · For: HIV; HIV Infections
Sites: Birmingham, Alabama; Phoenix, Arizona; Little Rock, Arkansas · 102 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- bone density decreased1,067
- bone loss609
- osteonecrosis608
- chronic kidney disease578
- tooth loss565
- multiple fractures529
- renal failure509
- osteoporosis433
- renal injury426
- skeletal injury373
- pain368
- emotional distress353
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2015 | 1 |
| 2018 | 31 |
| 2019 | 302 |
| 2020 | 942 |
| 2021 | 418 |
| 2022 | 337 |
| 2023 | 271 |
| 2024 | 224 |
| 2025 | 156 |
| 2026 | 72 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Symtuza (Darunavir/Cob/Emtri/Tenof Alaf)
2024 spending
$448M
Beneficiaries
10,616
91,050 claims
Per beneficiary
$42,244
$154.88 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $336,497,871 |
| 2021 | $385,325,868 |
| 2022 | $429,047,550 |
| 2023 | $468,770,365 |
| 2024 | $448,466,477 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Symtuza® in clinical practice.
Luis Casado J, Fontecha M, Monsalvo M, et al. · Enferm Infecc Microbiol Clin (Engl Ed) 2018 · Clinical Trial, Phase III
- Maintenance therapy with dolutegravir and lamivudine versus bictegravir, emtricitabine, and tenofovir alafenamide in people with HIV (PASO-DOBLE): 48-week results from a randomised, multicentre, open-label, non-inferiority trial.
Ryan P, Blanco JL, Masia M, et al. · Lancet HIV 2025 · Multicenter Study, Randomized Controlled Trial
- A crucial role for novel miR-12137-3p in supporting weight gain in treatment naïve HIV-infected patients on antiretroviral therapies.
Majumdar N, Pokharel BR, Williams F, et al. · J Transl Med 2026 · Clinical Trial, Phase IV, Randomized Controlled Trial
- Pharmacokinetic boosting of olaparib: A randomised, cross-over study (PROACTIVE-study).
Overbeek JK, Guchelaar NAD, Mohmaed Ali MI, et al. · Eur J Cancer 2023 · Randomized Controlled Trial, Multicenter Study
- The Drug-Drug Interaction Profile of Presatovir.
Xin Y, Weng W, Murray BP, et al. · J Clin Pharmacol 2018 · Clinical Trial, Phase I, Research Support, Non-U.S. Gov't
- Population Pharmacokinetics of Boosted-Elvitegravir in HIV-Infected Patients.
Custodio JM, Gordi T, Zhong L, et al. · J Clin Pharmacol 2016 · Clinical Trial, Phase I, Clinical Trial, Phase II
Sponsor: Johnson & Johnson (Janssen)
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.